NCT03764137 2025-01-31
Panitumumab
University of Alabama at Birmingham
Phase 1/2 Withdrawn
University of Alabama at Birmingham
Sadat City University
Faron Pharmaceuticals Ltd
University of California, Irvine
Roswell Park Cancer Institute
University of Southern California
University of British Columbia